{"id":"anti-egfr-or-bevacizumab","safety":{"commonSideEffects":[{"rate":"15%","effect":"Hypertension"},{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Fatigue"},{"rate":"6%","effect":"Headache"},{"rate":"5%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bevacizumab is a recombinant humanized monoclonal antibody that binds to VEGFA, preventing its interaction with its receptors and thereby inhibiting angiogenesis.","oneSentence":"Inhibits vascular endothelial growth factor A (VEGFA)","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:02.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Glioblastoma"}]},"trialDetails":[{"nctId":"NCT04181060","phase":"PHASE3","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-28","conditions":"Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":300},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT02971501","phase":"PHASE2","title":"Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-27","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8","enrollment":7},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT04485013","phase":"PHASE1","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","status":"RECRUITING","sponsor":"Tizona Therapeutics, Inc","startDate":"2020-07-14","conditions":"Cancer","enrollment":240},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT04787341","phase":"PHASE2","title":"PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2020-12-15","conditions":"Colorectal Cancer","enrollment":214},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT07318805","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-16","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer","enrollment":260},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT01552434","phase":"PHASE1","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-03-16","conditions":"Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma","enrollment":155},{"nctId":"NCT04595266","phase":"PHASE2","title":"Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2021-06-29","conditions":"Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer","enrollment":48},{"nctId":"NCT07124793","phase":"PHASE2","title":"A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-08-31","conditions":"EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer","enrollment":60},{"nctId":"NCT07044908","phase":"PHASE1, PHASE2","title":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-30","conditions":"RAS/BRAF Wild Type Colorectal Cancer","enrollment":72},{"nctId":"NCT07065435","phase":"PHASE2","title":"RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"HER2 + Breast Cancer","enrollment":74},{"nctId":"NCT06276283","phase":"PHASE2","title":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2023-02-15","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT03169764","phase":"PHASE1, PHASE2","title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03169777","phase":"PHASE1, PHASE2","title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT03197571","phase":"PHASE1, PHASE2","title":"QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Urothelial Carcinoma","enrollment":""},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT06575127","phase":"PHASE2","title":"Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-08-17","conditions":"Neoplasm Malignant, Colon Cancer Stage 4","enrollment":60},{"nctId":"NCT03387111","phase":"PHASE1, PHASE2","title":"QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-01-09","conditions":"Squamous Cell Carcinoma","enrollment":4},{"nctId":"NCT05039944","phase":"PHASE2","title":"SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies","status":"TERMINATED","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2021-11-30","conditions":"Colorectal Cancer","enrollment":7},{"nctId":"NCT04426825","phase":"PHASE2","title":"A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-09-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":23},{"nctId":"NCT04147351","phase":"PHASE2","title":"A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-04-10","conditions":"NSCLC Stage IIIB~IV","enrollment":22},{"nctId":"NCT06314997","phase":"PHASE2","title":"Dynamic Changes in Circulating Tumour Cells Protein Expression","status":"RECRUITING","sponsor":"Matteo's Friends","startDate":"2019-01-14","conditions":"Recurrence Free Survival","enrollment":150},{"nctId":"NCT01910610","phase":"PHASE3","title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-10-30","conditions":"Colorectal Cancer Metastatic","enrollment":464},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT06226857","phase":"PHASE3","title":"Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"City Clinical Oncology Hospital No 1","startDate":"2024-01-17","conditions":"Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation","enrollment":355},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT00946712","phase":"PHASE3","title":"S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2009-07-15","conditions":"Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma","enrollment":1333},{"nctId":"NCT05675033","phase":"PHASE2","title":"Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-01-10","conditions":"Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor","enrollment":50},{"nctId":"NCT04355858","phase":"PHASE2","title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-05-01","conditions":"Breast Cancer, Metastatic Cancer","enrollment":319},{"nctId":"NCT02292758","phase":"PHASE2","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2014-12-12","conditions":"Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7","enrollment":36},{"nctId":"NCT02715531","phase":"PHASE1","title":"A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-04-06","conditions":"Solid Tumor","enrollment":243},{"nctId":"NCT01532089","phase":"PHASE2","title":"Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2012-03-16","conditions":"EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":88},{"nctId":"NCT04517526","phase":"PHASE2","title":"Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Cancer Hospital, China","startDate":"2020-11-01","conditions":"Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT","enrollment":60},{"nctId":"NCT04148898","phase":"PHASE2","title":"Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2019-11-01","conditions":"Leptomeningeal Metastasis, Non-small Cell Lung Cancer, EGFR Activating Mutation","enrollment":80},{"nctId":"NCT00043823","phase":"PHASE1, PHASE2","title":"Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-08-01","conditions":"Lung Cancer","enrollment":41},{"nctId":"NCT02831842","phase":"","title":"A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-09","conditions":"Colorectal Cancer","enrollment":4278},{"nctId":"NCT00619424","phase":"PHASE1","title":"A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-15","conditions":"Lung Cancer, Non-Small Cell","enrollment":58},{"nctId":"NCT02930954","phase":"PHASE2","title":"Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance","status":"UNKNOWN","sponsor":"Caicun Zhou","startDate":"2016-11","conditions":"Non-small-cell Lung Cancer","enrollment":180},{"nctId":"NCT02701231","phase":"NA","title":"Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-11","conditions":"Lung Neoplasms","enrollment":200},{"nctId":"NCT00365391","phase":"PHASE2","title":"Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-08","conditions":"Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer","enrollment":27},{"nctId":"NCT00356889","phase":"PHASE2","title":"Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-05","conditions":"Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Gastrointestinal Cancer","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28623,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["monoclonal antibody anti EGFR (RASwt) or Bevacizumab (RASmut)"],"phase":"phase_2","status":"active","brandName":"Anti-EGFR or Bevacizumab","genericName":"Anti-EGFR or Bevacizumab","companyName":"Grupo Espanol Multidisciplinario del Cancer Digestivo","companyId":"grupo-espanol-multidisciplinario-del-cancer-digestivo","modality":"Biologic","firstApprovalDate":"","aiSummary":"Inhibits vascular endothelial growth factor A (VEGFA) Used for Colorectal cancer, Non-small cell lung cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}